TY - JOUR
T1 - Summary from the First Kidney Cancer Research Summit, September 12-13, 2019
T2 - A Focus on Translational Research
AU - Choueiri, Toni K.
AU - Atkins, Michael B.
AU - Bakouny, Ziad
AU - Carlo, Maria I.
AU - Drake, Charles G.
AU - Jonasch, Eric
AU - Kapur, Payal
AU - Lewis, Bryan
AU - Linehan, W. Marston
AU - Mitchell, Michael J.
AU - Pal, Sumanta K.
AU - Pels, Kevin
AU - Poteat, Susan
AU - Rathmell, W. Kimryn
AU - Rini, Brian I.
AU - Signoretti, Sabina
AU - Tannir, Nizar M.
AU - Uzzo, Robert G.
AU - Wood, Christopher G.
AU - Hammers, Hans
N1 - © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.
AB - Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.
KW - Animals
KW - Carcinoma, Renal Cell/genetics
KW - Clinical Trials as Topic
KW - Humans
KW - Kidney Neoplasms/genetics
KW - Randomized Controlled Trials as Topic
UR - http://www.scopus.com/inward/record.url?scp=85086047769&partnerID=8YFLogxK
U2 - 10.1093/jnci/djaa064
DO - 10.1093/jnci/djaa064
M3 - Article
C2 - 32359162
SN - 0027-8874
VL - 113
SP - 234
EP - 243
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 3
ER -
